Association of CNTNAP2 gene Variants with Palestinian Autism Patients by مهند سعيد سليمان القيق & Mohannad said suleiman qeeq
 
 
Deanship of Graduated Studies                                                               
Al-Quds University 
 
 
 
 
Association of CNTNAP2 gene Variants with Palestinian 
Autism Patients 
 
 
 
Muhanad Said Suleiman Al-Qiq 
 
 
 
M.Sc. Thesis 
 
 
 
Jerusalem - Palestine 
 
1440/2018
  
Association of CNTNAP2 gene Variants with Palestinian 
Autism Patients 
 
 
 
 
Prepared by: 
Muhanad Said Suleiman Al-Qiq 
 
 
B.SC in Pharmacy Al-Quds University Palestine 
 
Supervised by:  
 
Dr.Hisham Darwish  
 
 
A thesis submitted in partial fulfillment of requirements for 
the degree of master of biochemistry and molecular biology 
from the biochemistry and molecular biology department           
faculty of medicine /Al-Quds University 
 
1440/2018 
Al Quds University 
Deanship of Graduate Studies 
Biochemistry and Molecular Biology Department 
Thesis approval 
Association of CNTNAP2 gene Variants with Palestinian Autism Patients 
Prepared by: Muhanad Said Suleiman Al-Qiq 
Registration Number: 21412369 
Supervisor: Dr.Hisham Darwish 
Master thesis submitted and accepted, Date: 26/10/2018 
The names and signatures of the examining committee members are as 
Follows. 
1-Head of Committee: Dr Hisham Darwish   Signature …………. 
2-Internal Examiner:  Dr Kifaya Azmi           Signature …………. 
3-External Examiner: Dr Muhanad Khdeir   Signature …………. 
Jerusalem- Palestine 
1440 - 2018 
  
 
Dedication 
  
 
To my family…  
To my friends… 
To my Teachers... 
 
To all the people who supported me  
 
 
 
 
 
Muhanad Said Suleiman Al-Qiq  
 
 
 
 
 
 
 
 
 
 
I 
 
 
 
 
 
 
 
Declaration: 
 
I certify that this thesis submitted for the degree of master degree in Biochemistry and 
molecular biology is the results of my own research work, except where otherwise 
acknowledged. The results in this study has not been submitted for any other degree or 
publication in other universities or institution  
 
Signed: 
 
Muhanad Said Suleiman Al-Qiq  
 
Date: 26/10/2018 
 
 
 
 
 
 
 
 
II 
 
 
 
Acknowledgment 
 
I would thank my supervisor Dr.Hisham Darwish for his constant gaudiness and the 
unprecedented effort and time he invested in this work. I also deeply thank Rawan 
Yasmeen, Jod, societies in Ramallah, Farah society in Nablus and AL-Amal and Ghad 
societies in Jenin for their valuable help and assistance. My deep thanks and appreciation 
extends to the patients and their families for their participation in this study. The support 
of my family, teachers and friends is also deeply appreciated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III 
 
Abstract  
Autism is a neuro developmental disorder that involve various defects with vary severity such as 
lack of communication, social behavior or speech development. So far, the cause of autisms is still 
unknown; however, it is thought that genetic background might play a major role in the disorder. 
Various variants within the CNTNAP2 gene were linked to autism in many populations. Our 
objective focused on investigating the association of selected polymorphisms in the CNTNAP2 
gene with Autism and its clinical symptoms. 
A case control study was conducted between 45 autism patients and 145 healthy individuals. Using 
PCR-RFLP technology and direct DNA sequencing regarding to specific studied single nucleotide 
polymorphisms within the gene. The correlation between the genotype distribution and allele 
frequency between autism patients and healthy individuals and the clinical symptoms of the 
disease was analyzed using Pearson chi squared test (SPSS 22).   
No significant association could be detected between the rs 2710102 and rs 7794745 variants 
between the autism patients and control subjects .significant correlation was evident between 
specific genotype interaction between the two SNP sites and the disease. Specific genotype 
association between one specific SNP variant in rs 2710102 and the ability for self-expression 
was evident.  
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Chapter One  
 
 
Introduction 
 
1.1. Background 
 
Autism came originally from a Greek word means “self”. A physician named Eugen Bleuler first 
used the autism term in 1911 referring to symptoms in schizophrenia. Later, in 1944 and 1943 two 
American psychiatrics Leo Kanner and Hans Asperger took the pioneering step in redefying autism 
as individual disease with varying onset of psychological symptoms, being what is called Asperger 
syndrome is the milder case ("Autismus Hamburg - Was ist Autismus", 2018). 
Recently Autism spectrum disorder ASD is defined according to American Psychiatric Association 
by deficits in social communication and social interaction on many levels, such as deficits in social 
interchange, nonverbal communicative behaviors used for social interaction, and skills in 
developing, maintaining, and understanding relationships (American Psychiatric Association, 
2013). Most of autism patients fail to achieve independency in adult life. In fact, minor percentage 
lived on their own or had constant jobs. The most patients needed help from their families and 
failed to be independent (Howlin, Goode, Hutton & Rutter, 2004). About 15-47% of patients 
achieved improvement in symptoms upon development, however at 2 years of age the symptoms 
begin to appear again and lose the improvement in speech and social skills. (Stefanatos, 2008) For 
many years, Autism and other closely related neurodevelopmental disorder, which are also 
considered subtypes of Autism such as Asperger syndrome, Rett syndrome, childhood 
disintegrative disorder, and pervasive developmental disorders, were diagnosed individually as a 
single condition according to the Diagnostic and Statistical Manual of Mental Disorders (DSM 
IV). In the last edition of the DSM , all of these subtypes are included under one classification 
known as Autism spectrum disorder (ASD) and the indicated subtypes are no longer diagnosed 
separately as individual disorder but under one condition named ASD with varying severity 
(American Psychiatric Association, 2013).   
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1.2. Diagnosis: 
According to DSM 5, ASD diagnosed according to the following criteria: 
A. Permanent lack of ability in social communication and interaction that include: 
 
1. Difficulties in social and emotional contact such as, showing no interest in expressing feeling 
or interest or emotions. Also showing malfunction in responding to social interaction.  
2. Difficulties in nonverbal communication like failure to maintain eye contact or proper body 
language.   
3. Difficulties in forming and comprehending relationship, like showing no interest in making 
friends. 
B. Restrained and repetitive form of behaviors, showing interest or activities as specified by 
at least two of the followings:  
 
1. Repetitive motor movement like stereotyped playing style or using of objects or pattern of 
speech  
2. Persistent attachment to certain routine or forms of verbal or non-verbal behavior Like eating 
the same food or taking the same route every day and showing extreme rage for small changes and 
modifications   
3. Intense and abnormal concentration in certain interests in unusual objects and showing strong 
attachment  
4. Showing hyper or hypo reactivity in sensory input or abnormal reaction to sensory changes in 
environment, like abnormal response to sound, temperature or pain  
C. Symptoms must exist in early childhood and become fully visible later until social demands 
overwhelm the limited capability 
 
D. Symptoms cause clinically significant deficits in social functioning. 
 
 
 
3 
 
Severity levels for the above-mentioned symptoms ranges from level 1 “requiring support” 
Level 2 “requiring subnational support” and level 3 “requiring very substantial support”. 
A major percentage of ASD cases have a comorbidity with many psychiatric disorders such 
Attention-defective/ hyperactivity activity disorder (ADHD), or obsessive-compulsive disorder 
(OCD), or depression (Belardinelli & Raza, 2016). 
 
 
 
1.3. Epidemiology 
The prevalence of autism spectrum disorder across the U.S. and other developed countries have 
approached 1% of the population, with similar results in child and adult patients (American 
Psychiatric Association, 2013). A recent study in USA reported the prevalence of ASD among 
children was 14.6 per 1,000 (1 in 68), with 23.6 per 1,000 boys and 5.3 per 1,000 girls (Christensen 
et al., 2016). Very limited Studies regarding autism prevalence were performed in the Middle East. 
One study in the Saudi Arabia estimate the prevalence of autism is 18 per 10000 (Al-Salehi, Al-
Hifthy & Ghaziuddin, 2009). In UAE until 2007, the estimate is 58 per 10000 (Eapen, Mabrouk, 
Zoubeidi & Yunis, 2007). The prevalence in Oman is 1.4 ASD patients per 10000 with boys 
representing 75% of the cases (Al-Farsi et al., 2010). A study published in Israel reports the 
prevalence of children with ASD was 3.6 per 1000 in 2003 with an increase of three times, 
comparing with data from 1986, which was 1.2 per 1000. In addition, higher prevalence was seen 
in males with 5.7 per 1000 then females with 1.2 per 1000 (Gal, Abiri, Reichenberg, Gabis & 
Gross, 2011). A Later study regarding Israeli population in 2010 found a prevalence of 0.48 % of 
children aged between 1-12 years old and 0.65 % of children aged 8 years old (Davidovitch, Hemo, 
Manning-Courtney & Fombonne, 2012). In Palestine, no published data is available regarding the 
prevalence of autism among the population. Figure 1.1 summarizing a meta-analysis study 
reviewing autism prevalence studies worldwide from 1966 to 2004 as noticed the increase in 
autism incidence over the years, which is in part could be due to changing of diagnosing criteria 
over the years (Williams, 2005). 
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Figure 1.1: diagram summarizing prevalence study in autism from studies older than 1980 to 2010, designated at 5 
years intervals ("How prevalent is autism? - Autism Reading Room", 2018) 
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1.4. Economic burden 
Economical cost of autism in the UK and US was $2.4 million and $2.2 million respectively during 
the lifetime of autistic patients with intellectual disability. In addition, $1.4 million for those 
without intellectual disability. This economic burden was much higher in adults than children 
(Buescher, Cidav, Knapp & Mandell, 2014). Another study in the US calculated the economic 
burden of autism in 2015 to be $ 268 billion and expected to rise to $461 billion in 2025. This 
makes autism in line with economic burden for diabetes and ADHA, and higher than stroke and 
hypertension (Leigh & Du, 2015). Moreover, Autistic patients have low contribution in 
employment or education after high school. In fact, more than 50% have no enrolment in jobs or 
education after high school and only 34.7% enroll in college after high school, which makes them 
with the lowest enrolment rate in employment compared with other normal youth, and highest rate 
of no contribution in employment among other disabilities (Shattuck et al., 2012). 
 
 
 
1.5. Risk factors 
 
There are numerous risk factors regarding reports in literatures with the followings represent most 
significant. 
 
1.5.1 Maternal and paternal age 
 
 Many studies have confirmed a trend of higher maternal age associated in increased chances of 
having child with autism. One study in the US, which recruited 3013 children by age of 36 months, 
found that child of mothers aged younger than 24 years of age had lower chance of any early infant 
diagnosis, while mothers who aged older than 30 years old had a greater chance of having child 
with early autism diagnosis (Manning et al., 2011). A study in Sweden reported that maternal aged 
higher than 40 had a significant risk of having child with autism, with odd ratio 2.5 (Haglund & 
Källén, 2010). Regarding Paternal age many studies showed that advance paternal age is 
considered a major risk factor regarding autism. In fact, father’s age linked to higher incidence of 
de novo mutation, which possibly linked to disease such as autism and schizophrenia (Kong et al., 
2012). In one study done in Sweden showed that men aged more than 50 years old had 2.2 times 
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greater chance of having children affected with autism than children of men aged <29 years old 
(Hultman, Sandin, Levine, Lichtenstein & Reichenberg, 2010) . Another study found that fathers 
aged more than 40 years old were more likely to have offspring with autism by 3.3 times than of 
offspring of fathers aged less than 20 years old (Buizer-Voskamp et al., 2011). A study done in 
Israel has revealed that there is a significant association between paternal age and the risk of 
developing autism, in which Childs of fathers aged 40 years or older had increased chance of 5.75 
times compared with Childs of men aged younger than 30 years old (Reichenberg et al., 2006). 
The mixture of maternal and paternal age was evaluated. and revealed that the increase by 10 years 
in maternal and paternal age correlated significantly with the risk of developing autism. Moreover, 
both of their age independently affects their offspring regarding autism. (Croen, Najjar, Fireman 
& Grether, 2007) 
 
 
 
1.5.2 Offspring sex 
 
 Child gender is considered one of the major risk factor regarding autism. In fact, males are 3.4 
times more likely to be diagnosed with autism than females in US population. (Christensen et al., 
2016). Another study in the same population suggest that most of children diagnosed with autism 
are males with percentage of 81% (Giarelli et al., 2010). In Israel, also most of children diagnosed 
with autism are males with percentage of 84.4 %( Gal, Abiri, Reichenberg, Gabis & Gross, 2011). 
In Palestine, most diagnosed patients with autism are males reaching about 90 % (unpublished 
data).  
 
1.5.3 Prenatal and neonatal environment 
 
A meta-analysis study discussing the relationship between prenatal and neonatal environment and 
chances of having autism. In which 60 prenatal or neonatal factor were investigated it was  found 
that the factors most linked to autism risk were abnormal representation, birth injury or trauma, 
fetal stress, umbilical cord complication, multiple birth, maternal hemorrhage, low birth weight, 
summer birth, small gestational birth, congenital malformation, feeding difficulties, neonatal 
anemia ABO or RH incapability and hyperbilirubinemia. However, factors that are not associated 
with autism include anesthesia, post term birth, high birth weight and assisted vaginal delivery 
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(Gardener, Spiegelman & Buka, 2011). Prenatal exposure to certain chemicals and medications 
such as valproic acid, ethanol, thalidomide and misoprostol proved to increase risk of autism 
(Dufour-Rainfray et al., 2011.Strömland, Nordin, Miller, Akerström & Gillberg, 2008). Regarding 
smoking in pregnancy, one study suggested, that there is increased risk for a child being diagnosed 
with autism by 1.4 times, if his mother was smoker during prenatal stage compared with 
nonsmoker mothers (Hultman, Sparén & Cnattingius, 2002). 
 
1.5.6 Vitamins levels 
 
Level of 25-hydroxy vitamin D has been found to be significantly lower in autistic children versus 
normal ones. In fact, 40% of these children whom were diagnosed with autism were vitamin D 
deficient (Mostafa & AL-Ayadhi, 2012). Regarding Folic acid intake during pregnancy, there is a 
clue that pregnant women who took folic acid during pregnancy had lower risk of having autistic 
child compared with women who did not took folic acid during pregnancy (Wang, Li, Zhao & Li, 
2017). However, one study reported that highe intake of folic acid and B12 during pregnancy are 
associated with increased chance of having child with autism. Moreover, the high level of B12 and 
folic acid at birth had an increased the risk by 2.5 times (Raghavan et al., 2017). 
 
1.6. Morphological features and minor anomalies 
 
 Children diagnosed with autism have distinguishable morphological features such as protruding 
forehead, lack of symmetrical feature in the face, and hair whorls that have been found 
significantly associated with autistic children compared with health individuals (Ozgen, 
Hellemann, de Jonge, Beemer & van Engeland, 2012). Minor physical anomalies, such as 
abnormal physical characteristic variation that themselves are not dangerous, those anomalies were 
found to strongly associate with autistic children. Examples on those anomalies include low set 
ears and high palate (Ozgen, Hop, Hox, Beemer & van Engeland, 2008). In fact, those 
distinguishable physical features of autistic children could be used as diagnosed tool; one study 
was able to construct a predictive model based on such features (Ozgen, Hellemann, de Jonge, 
Beemer & van Engeland, 2012). Regarding brain anatomy, brain and head overgrowth especially 
in the prefrontal cortex has been noticed in autistic children aged from 9 -18 months.  
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In fact, autism patients had 67% higher number of neurons in prefrontal cortex than normal 
individuals and 79% increase in neurons in the dorsolateral prefrontal cortex, and 29% more 
neurons in the mesial prefrontal cortex. It was found that brain weight was significantly higher in 
autism patients than normal individual was. It is worth to mention that the prefrontal cortex is the 
center for emotional, communication and cognitive functions (Courchesne et al., 2011). Figure 1.2 
illustrates parts of the brain being affected with autism.  
 
 
 
Figure 1.2: Autisms effect on brain (Islam et al., 2015) 
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1.7. Role of Genetics 
There is no definitive cause of autism, and since its discovery, speculation of its cause has 
overlapped between biological and psychological factors but not until the twin studies in 1970s 
and 1980s, which suggested some evidence for a genetic cause. The first twin study in 1977 
recruited 21 twin pairs with at least on twin showed signs of autism. 11 were monozygotic and 10 
dizygotic. It was revealed that the monozygotic pairs showed significantly higher concordance for 
autism than the dizygotic ones. This study represented the first core of genetic evidence for autism 
although the mode of inheritance was not clear (Folstein & Rutter, 1977). 
Another study done in population of Denmark, Finland, Iceland, Norway and Sweden which 
recruited 21 twin pairs (11 monozygotic, and 10 dizygotic) with same sex under age of 25. 
Concordance rate for autism was 91% in the monozygotic twin versus 0% dizygotic twin pair 
(Steffenburg et al., 1989). A Later study on autistic twins done in the British population has showed 
that 60% of the monozygotic pairs had concordance for autism while no concordance was evident 
in dizygotic pairs (Bailey et al., 1995). An expanded twin study which recruited the largest sample 
with 277 twin pairs (210 dizygotic and 67 monozygotic) aged 18 years of old or younger with at 
least one twin diagnosed with autism. It was revealed that monozygotic twins have significantly 
higher concordance rate with 88%, compared with dizygotic twins that have 31 % concordance 
rate (Rosenberg et al., 2009). Regarding family history and sibling genetics, one study has 
confirmed that the risk of developing autism increases by 22 times in children who has sibling 
affected with autism, and the risk of children being diagnosed with autism increased twice as high 
if their mother have a psychiatric disorder (Lauritsen, Pedersen & Mortensen, 2005). In fact, there 
is support if two autism patients are diagnosed in a family then the chances of having another child 
with autism could reach 25%. Moreover, the odds for having one or more traits of autism is 30% 
in adult sibling (Folstein & Rosen-Sheidley, 2001). 
Many Minor cases of autism are common related to underlying medical disorders like fragile x 
syndrome or tuberous sclerosis complex. In fact, cytogenetic disorders and single gene 
abnormalities together with other rare diseases represent <10% of autism cases, making the 
remaining 90% known as idiopathic autism (Muhle, Trentacoste & Rapin, 2004). All the discussed 
studies confirmed that there is a hereditary component that participate in Autism risk. However, 
as single gene disorders such as, fragile x syndrome are ignored in major cases of autism, it would 
be more reasonable to study suspected single gene polymorphisms (Duchan and Patel, 2012). 
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1.8. Role of Epigenetic 
 
Epigenetic is the study of changes and alteration to DNA that do not affect its structure, such as 
methylation or acetylation or post translational modification segments of the DNA that eventually 
lead to enhanced or reduced gene expression. (Dupont, Armant & Brenner, 2009). DNA 
methylation has been noticed in neurological disease such as Alzheimer and schizophrenia. in a 
cohort study for those two diseases targeting the temporal neocortex of 125 individuals whose age 
ranges from 17 weeks to 104 years old. A pronounced rise was shown in methylation state in 
5’CpG Island of many genes, which have role in CNS growth and development such as GABRA2, 
HOXA1, and NEUROD2. (Siegmund et al., 2007). 
Another example related to autism is Rett syndrome it is known that this syndrome is due to a 
mutation in methyl-CpG-binding protein2 (MeCP2), which act as inhibitor for gene expression at 
the level of transcription that bind and inhibit specifically methylated genes. Epigenetic alterations 
ware also noticed in fragile X syndrome and Huntington's disease (Ptak & Petronis 2010). Another 
study on 394 patients and 500 controls found that hypo-methylated state of ERMN gene and other 
different loci was significantly associated with autism (Homs et al., 2016).  
An additional study investigated the impact of methylation pattern of the oxytocin receptor gene 
(OXTR) promoter on autism. The results revealed that hypomethylated state of the OXTR 
promoter at specific region (MT1 and MT3) has significantly associated with autism. (Elagoz 
Yuksel, Yuceturk, Karatas, Ozen & Dogangun, 2016). 
 
 
1.9. Mortalities 
 
One cohort study in Denmark calculated the mortality risk of autism and found that individuals 
diagnosed with autism has twice chance of death versus normal individuals with mortality ratio 
higher in female and the trend remained the same between 1993 to 2008 . In this study 314 autistic 
patients were recruited, where 26 died, and 12 of them their death was related to epilepsy 
(Mouridsen, Brønnum-Hansen, Rich & Isager, 2008). Another study in Sweden has calculated the 
death rate in 120 autistic patient and found it was 5.6 times higher than expected; also, the rate was 
higher in females (Gillberg, Billstedt, Sundh & Gillberg, 2009). It is noteworthy to mention that 
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the patients recruited in both studies had other medical disorders like epilepsy. Therefore, it is hard 
to conclude that autism alone was the main responsible cause for the increased death rate (Gillberg, 
Billstedt, Sundh & Gillberg, 2009). 
Moreover, one systemic review study has calculated the percentage of death among autism 
associated with epilepsy to be 7-30 % in all the relevant studies, while other causes of death ranged 
from circulatory, respiratory, and malignancy complications. (Woolfenden et al., 2012) 
 
1.10. Treatment 
 
Until now, no cure for autism is currently available. Because the exact cause is not definite, but 
treatment approaches are followed to help manage symptoms. These include:  
 
1.10.1. Psychosocial treatment 
 
This treatment, which involves therapies, that are linked to behavior changes based on learning 
system such as applied behavioral analysis (ABA). ABA system depends on methods and 
principles which aim to instruct, guide, motivate, and train the patient toward certain behavior in 
order to induce alteration in the patient interest toward certain activities or skills weather, in speech 
or in communication and social behavior (Vismara & Rogers, 2010). Such treatment methods 
proved its efficacy, and was possible to regain in large percentage of autistic patients normal 
intellectual, and learning skills and consequently able to fit in normal schools (Lovaas, 1987). 
Another meta-analysis study aimed to validate the effectiveness of ABA method concluded that 
prolonged and intensive ABA is effective in regaining normal behavior, speech improvement and 
social communication rather than improvement in IQ (Virués-Ortega, 2010). 
ABA method has many limitations such as the prolonged period it takes to notice its positive 
outcome, in addition to being expensive (Melissa & Dineen, 2016) 
 
1.10.2 Dietary treatment 
 
Nutritional restriction food proved its efficacy in improvement of autism symptoms. Studies had 
proved the gluten and casein free diet are effective in autism patients, and positive results are seen 
within 3 months (Kawicka and Regulska-Ilow, 2013). Another dietary treating strategy called 
ketogenic diet, which is rely mainly on low carbohydrates and high fat foods. In a pilot study which 
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included 30 children, this diet produced positive outcome in improvement of autism symptoms 
when applied for six months (Evangeliou et al., 2003). 
Another strategy is to limit oxalate from diet. It was observed that autistic patients have 3 times 
increase in oxalate plasma level compared with normal levels, which raises question whether the 
oxalate is crucial in pathogenesis of autism (Konstantynowicz et al., 2012). It is worth to note that 
dietary supplements such as omega-3 fatty acid, vitamin A, vitamin B6 and magnesium, have 
produced a positive effect on autism symptoms improvement (Kawicka and Regulska-Ilow, 2013). 
 
1.10.3 Pharmacological treatment 
 
Risperidone, which is atypical antipsychotic that work by blocking dopamine and serotonin 
receptors.in a randomized double blind study efficacy and safety of risperidone in treating autism 
symptoms had been studied compared with placebo , it has resulted in significant decrease in 
irritability compared with placebo. Moreover, it’s the only FDA proved drug for treating symptoms 
in autism. However, it was noticed many side effects such, increased appetite, fatigue, dizziness, 
drowsiness and drooling. Risperidone was also safe and showed positive outcome in treating 
aggression and self-harm behavior (McCracken et al., 2002). 
Another pharmacological agent called Aripiprazole, which is a partial dopamine agonist,  
has been studied in term of efficacy and safety in autistic patients, and it has been found in double 
blind randomized study that is safe and effective in treating irritability in both adult and autistic 
children (Owen et al.,2009). 
Another drug called Olanzapine, which is dopamine receptor antagonist; its efficacy has been 
studied on autism symptoms in an open-label trial recruited 40 children with a dose of 5-10 mg 
daily for 12 weeks. It was found that the drug has significantly lowered many symptoms associated 
with autism, such as irritability, hyperactivity, and inappropriate speech, and stereotyped behavior 
(Fido & Al-Saad, 2008). 
 
1.11 Literature review 
 
Many methods have been used to identify genes linked to autism including, linkage analyses 
studies, low scale genetic association studies, genome wide association studies (GWAS), 
expression profiling, experimental studies and genome wide copy number variant. Meta-analysis 
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reported over 2193 genes, 2806 SNPs/VNTRs, 4544 copy number variation and 158 linkage 
regions that have been linked to autism. Those genes were strongly involved in pathways such as, 
synapse transmission, Neuroactive ligand receptor interaction, axon guidance, transmission of 
nerve impulse and neuron differentiation. Those efforts lead to establish a database called 
AutismKB (Xu et al., 2011). Among those autism candidate genes, this thesis focuses on selected 
CNTNAP2 gene polymorphisms and its correlation with autism and the various biochemical 
complications of autism.  
 
1.11.1 CNTANP2 gene 
 
The Contactin associated protein gene (CNTNAP2) encodes a neuronal Trans membrane protein 
(Caspr2) which is a member of the neurexin super family involved in neural-glia interactions and 
clustering of potassium channels in myelinated axons (Poliak et al., 1999). The CNTNAP2 is the 
largest gene in the human genome containing 25 exons and represent 1.5% of chromosome 7 at 
7q35 (Nakabayashi & Scherer, 2001). (Figure 1.3)  
CASPR2 was first discovered in 1999 as a mammalian homolog of drosophila neurexin IV, and 
as new member of the neurexin super family, localized at the juxtaparanodes of the myelinated 
axons and associated with potassium channels (Poliak et al., 1999).as illustrated in figure 1.4  
 
 
  Figure 1.3: location of the CNTNAP2 gene (https://ghr.nlm.nih.gov/gene/CNTNAP2#location). 
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Figure 1.4: caspr2 protein localization (Lancaster & Dalmau, 2012). 
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CASPR2 contain seven domains, discoidin homology domain, laminin G domain, E= EGF like 
domain, FBG-like = fibrinogen –like region, TM = transmembrane protein, 4.1= protein 4.1 
binding domain and PDZ interaction domain (figure 1.4 and figure 1.5). The discoidin and 
fibrinogen domains function in cell-cell adhesion and extracellular matrix interaction, the four-
lamimin domains, and the epidermal growth factor domains are believed to function in receptor 
ligand interaction, migration, cell adhesion and differentiation while the rest of the protein are 
involved in protein- protein interaction. Interestingly caspr2 protein is highly conserved among 
other mammals with 94% and 99.5% similarity in mouse and chimpanzee, respectively (Rodenas-
Cuadrado, Ho & Vernes, 2013). 
The CNTNAP2 gene encodes five transcripts, Transcript CNTNAP2-001, CNTNAP2-201, and 
CNTNAP2-002, which are translated into protein. CNTNAP2 gene contain four non-coding exons 
(Poot, 2015). 
1.11.2 Molecular interaction in CNTANP2 gene leading to different 
neurological disorders 
CNTNAP2 expression is regulated by four transcription factors; storkhead box A1 (STOX1A), 
transcription factor 4 (TCF4), foorkhead box P1 (FOXP1), and foorkhead box P2 (FOXP2) 
(Rodenas-Cuadrado, Ho & Vernes, 2013). Interestingly de novo mutation in the transcription 
factor FOXP2 is linked to intellectual disability, autism and language impairment. In a case of two 
patients with de novo mutation in the FOXP2 had symptoms such as intellectual disability, autism 
behavior, mood liability, and physical aggressiveness and sever language impairment (Hamdan et 
al., 2010). This provide evidence on the potential importance of the CNTNAP2 gene regarding 
autism, as it is regulated by FOXP2  
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Figure 1.5: domains of CNTNAP2 gene product CASPR2 and their homology to Nrx-IV product. (Rodenas-
Cuadrado, Ho & Vernes, 2013). 
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Another evidence suggested a role for CNTNAP2 gene in neurodegenerative diseases such as 
Alzheimer. Van Abel and colleagues found that CNTNAP2 gene expression is reduced in 
hippocampus of Alzheimer disease patients  , and the mechanism is mediated by the transcription 
factor STOX1A which binds CNTNPA2 gene and down regulates its expression , while STOX1A 
expression is increased (Van Abel et al.,2012) 
Moreover, it was found that malfunction in the transcription factor forkhead box P2 (FOXP2) that 
bind to intron 1 of the CNTANP2 gene, and consequently modulate its function, affect language 
and speech abilities, which represent another clue on the importance of CNTNAP2 gene in 
language function (Peñagarikano & Geschwind, 2012). Another study investigated the effect of 
polymorphisms in the FOXP2 gene on various speech and language impairments. It was found 
that variant rs7758412 in FOXP2 is significantly associated with non-word repetition in 188 family 
trio with dyslexia disorder (Peter et al., 2010). A further study identified variants in the promoter 
region of CNTNAP2 gene (rs150447075, rs34712024 and rs71781329) that altered the 
transcription factors binding site and thus reduced gene expression in differentiated and 
undifferentiated neuroblastoid cells due to reduced promoter efficacy, and were found to be 
associated with autism behavior (Chiocchetti et al., 2014). 
1.11.3 Functional mutation in CNTNAP2 gene in different neurological 
disorders 
The first link of CNTNAP2 gene to cognitive abnormalities was in 2003. It has been found the 
abnormal expression of the CNTNAP2 gene is associated with Tourette syndrome and obsessive-
compulsive disorder, which was explained by disruption of repolarization of action potential as a 
result of defect in potassium channels that are related to CNTNAP2 function (Verkerk et al., 2003). 
In fact, it has been discovered that the CNTNAP2 gene contain 13 missense/nonsense mutations, 
and 282 single nucleotide variation (Poot, 2015). 
Utilizing methods such as molecular karyotyping and mutational analysis, it was revealed that a 
mutation in the CNTNAP2 and NRXN1 cause mental retardation, seizures, autism behavior, and 
breathing defects resembling symptoms of Pitt-Hopkins syndrome Deletion of exon 2-9 in the 
CNTNAP2 gene was found in patients with Pitt-Hopkins syndrome (Zweier et al., 2009). 
A study was done on a group of patients who belong to the Amish ethnic group. found that a single 
base mutation in the CNTNAP2 gene is associated with cortical dysplasia focal epilepsy (CDFE), 
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autistic behavior, hyperactivity language impairment, macrocephaly, weak or without tendon 
reflex, mental retardation rather than brain structural impairment such as unilateral dysplasia of 
the anterior temporal lope and malformation of the left striatum (Strauss et al., 2006).  Moreover, 
neuropathology revealed abnormal organization of the neurons, increased neuron density in 
hippocampus and temporal neocortex, and decrease in the staining levels for CASPAR2. The 
patients were homozygous for the mutation and their parents were heterozygous which suggest a 
recessive effect for the mutation, which suggests Mendelian inheritance (Strauss et al., 2006). 
In a case report which involve the same ethnic group, one girl previously found to have a 
homozygous mutation in CNTNAP2 gene rendered the gene inactive.  Had physical abnormalities 
such as large head circumference and lowered deep tendon reflexes as well as clinical 
manifestation such as abnormal development, seizures, periventricular leukemia, mental 
retardation, hepatomegaly and autism characteristics like abnormal eye contact, detached 
personality and other related behaviors (Jackman, Horn, Molleston & Sokol, 2009). Another 
evidence presented by Penagarikano and his colleagues, showed that mice devoted from 
CTNANP2, had defects in vocal communication, repetitive and restrictive behavior and abnormal 
social interaction. This replicates the human autism behavior and its worth to note that treating 
knockout mice with the FDA approved drug Risperidone for treating autism symptoms has 
replicated its effect in human in which it has reduced symptoms like hyperactivity and other 
repetitive behavior. However, it did not reduce social symptoms as test in chamber social 
interaction test or sensory hypersensitivity (Peñagarikano et al., 2011).  
One additional study reported microdeletion in a region that involves the first 3 exons of CNTNAP2 
gene in a Brazilian patient with stuttering and difficulties in learning and verbal communications. 
Remarkably, this deletion region of the CNTNAP2 gene is target for binding the transcription factor 
FOXP2, which add greater emphasis on the role of molecular interaction on the CNTNAP2 
function (Petrin et al., 2010). 
Another study reported a deletion in the CNTNAP2 gene in a patient who suffer from 
schizophrenia, epilepsy and cognitive impairment rather than decline in communication and self-
care capabilities. Since CNTNAP2 function in organization of myelinated axons, and schizophrenia 
patients show myelin dysfunction, it might explain its role in schizophrenia (Friedman et al., 2007). 
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1.11.4 Effect of CNTNAP2 variants on brain structure in autism or related 
disorder 
Using a neuroimaging technique, it was shown that the polymorphism rs7794745 in the CNTANP2 
gene affect the changes in white and grey matter morphology in the brain, in which homozygous 
risk allele (T) significantly lowered the grey and white matter volume on parts in the brain related 
to autism such as cerebellum, fusiform gyrus, occipital and frontal cortices. (Tan, Doke, 
Ashburner, Wood & Frackowiak, 2010). In another study through utilizing functional magnetic 
resonance imaging found that certain parts of the brain are differently activated according to the 
CNTNAP2 variants (Whalley et al., 2011). They revealed that the homozygous risk allele (CC) of 
SNP rs2710102 was associated with increased activation of the right inferior frontal gyrus/frontal 
operculum and decreased activity of the left superior parietal lobule. Moreover, in a different study 
regarding SNP rs7794745, persons with the homozygous risk allele (TT) had significant increase 
activation of the right middle temporal gyrus (Whalley et al., 2011). Interestingly the frontal 
operculum and middle temporal gyrus are one of areas that also involved in language functions, 
which indicates a role for variants in CNTNAP2 gene in language impairment by affecting brain 
structure (Whalley et al., 2011). Alarco´n and his colleagues documented one of the first linkages 
between autism and CNTNAP2 gene. In this study, they genotyped 2758 SNPs covering almost 
200 known genes. CNTNAP2 and other genes were selected as previous literature emphasized its 
role in autism like traits and further neurodevelopmental disorders. Through in situ hybridization 
in human fetal brain, they found that the CNTNAP2 gene was limited to the development of 
frontotemporal –subcortical circuits, striatum and dorsal thalamus noteworthy that these structures 
and circuitry of the brain an important for performing executive functions, joint attention, speech 
and language. They also found significant association between rs2710102 variant language 
malfunction in autism patients including age at first word (Alarcón et al., 2008). 
1.11.5 CNTNAP2 gene variants and neurological disorders 
The Effect of CNTNAP2 gene variants on schizophrenia and major depression have been 
investigated in Chinese Han population, specifically variant rs17236239 was found to significantly 
associate with schizophrenia Moreover, the variants rs2710102 and rs2710117 were found to be 
significantly associated with major depression in unrelated major depression patients comparing 
healthy control (Ji et al., 2013). It is noteworthy to mention that SNP rs2710102 in the CNTNAP2 
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gene was found to be associated with a form of language impairment like nonword repetition in 
dyslexia patients’ (Peter et al., 2010). An Additional study found significant association between 
the CNTNAP2 gene variants, rs2710102, rs759178, rs17236239 and rs2538976 in exon 13-15, 
and the risk of language impairment or autism (Whitehouse, Bishop, Ang, Pennell & Fisher, 2012). 
In a study on Chinese Han population, aimed to investigate the impact of different variants of the 
CNTNAP2 gene on speech sound disorder, which is related to communication capability. Using 
300 patients and 200 healthy individuals, they found that SNPs rs2538976, rs2710102 rs17236239, 
rs 2538976 and rs 2710117A have significant association with speech sound disorder (Zhao et al., 
2015). 
In selective Mutism, a social anxiety disorder which is related to autism in having impaired 
communication and social skills, it was examined whether SNPs in the CNTNAP2 gene have any 
impact on the disorder. The data showed that rs2710102 variants was significantly associated with 
the disorder in US population with odd ratio of 1.33 (Stein et al., 2011). 
1.11.6 Effect of CNTNAP2 gene variants on Autism in different populations 
Gene variants association studies regarding the CNTNAP2 gene provided an important resource 
for further understanding of ASD disease mechanisms. Of which showed strong association the 
rs7794745 (A/T) and the rs2710102(C/T) Variants in the CNTNAP2 gene with ASD, located 
between exon 2 and 3, and exon 13 and 14, respectively. As shown in figure 1.6 (Scott-Van 
Zeeland et al., 2010, Nascimento et al., 2016, Arking et al., 2008, Zare, Mashayekhi & Bidabadi, 
2017, Li et al., 2010, Peñagarikano et al., 2011). 
An evidence has been found in the Han Chinese population where SNPs in the CNTNAP2 gene 
were examined in 185 autism families using restriction fragment length polymorphism (RFLP). 
The authors found that patients with rs10500171 variant have increased risk for autism (Li et al., 
2010). 
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Figure 1.6. The location of variants within CNTNAP2 gene (Peñagarikano et al., 2011) 
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A recent study done on Iranian population, in which 200 autism patients and 260 healthy control 
were studied for the association of rs7794745 polymorphism in the CNTNAP2 gene, through PCR- 
RFLP. The data showed significant association between rs7794745 and autism (Zare, Mashayekhi 
& Bidabadi, 2017).Another study in the Brazilian population, involving 210 autism patients and 
200 healthy individuals, found that the homozygous allele TT in rs 7794745 variant is associated 
with Autism. However. They showed no significant association between rs2710102 variant and 
Autism (Nascimento et al., 2016) 
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1.12 Study objectives 
Due to the evidence that genetics play an important role in the development of autism. The 
CNTNAP2 gene emerge as a strong candidate for this role. It was decided to study the association 
of rs7794745 and rs2710102 Variants in the CNTNAP2 gene with Autism among Palestinian 
patients. This will potentially provide a predicting genomic marker for the disorder among 
suspected children and will allow early diagnosis and starting intervention at an early stage, which 
might increase the healing process and prevent increasing symptoms severity and consequently 
reducing therapy period and cost. This study is considered a pioneer trial regarding autism in the 
Palestinian population.  
 
Specific Objective 
To investigate the association between rs7794745 (A/T) and the rs2710102 (C/T) variants in the 
CNTNAP2 gene with Autism among Palestinian patients. 
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Chapter Two 
 
Methodology 
 
2.1 Study design 
This present study is a case control-based study conducted from November 2016 until March 2018. 
Subject recruitment with clinical and behaviors representations that rule their Autism diagnosis 
were based on the DSM criteria. In addition, the subjects were well diagnosed by pediatric 
neurologist or psychiatric in special clinics or different Autism school and societies. 
Demographic data like gender in addition to Medical records were obtained from patients records    
2.2. Study Area 
Our study areas included the various districts or governorate in west bank or east Jerusalem 
targeting Palestinian autism patients that are registered and cared by special societies in the region 
who provide mental, medical and social care for these patients. 
 
2.3. Study Subjects and blood sampling 
Many societies in the west bank and east Jerusalem were targeted with the aim to get about 100 
autism subjects, however because the number of authentically diagnosed patients were limited and 
the process of recruiting patients through direct family contact was very tedious and challenging, 
table 3.1 shows the distribution of patients for the various societies in the west bank. Palestinian 
patients residing in east Jerusalem could not be reached even after several attempts and promises 
to reach with no link at the end. The study subjects comprised of 45 patients firmly diagnosed with 
Autism by Neuro-specialists in private clinics and specialized societies who suffer from the various 
clinical complications of the disease and subjects that suffer mainly from other neurological 
disorder were excluded. The control subjects included 145 healthy individual. Blood samples were 
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collected from all subjects and transferred on ice to the Medical Research Center at Al-Quds 
University for genomic DNA purification and analysis.   
 
2.4. Methods of the study 
2.4.1 DNA extraction  
Genomic DNA from each sample extracted using the Epicenter DNA purification Kit (Master Pure 
TM Genomic DNA Purification Kit) according to the protocol described by the manufacturer as 
follows: 
1- Five ml of blood drawn into 5 ml K EDTA tube and centrifuged at room temperature for 15 
minutes at 1500 X g. The buffy coat (white blood cells) was withdrawn in 150 µl volume and 
transferred into 1.5 ml Eppendorf tubes.  
2- 0.6 ml Lysis buffer 1 (10mMTris-HCl, 400 mM NACL and 2mM NA2EDTA, pH 8.2) added 
and tubes gently inverted 6-8 times to mix, and the bottom of the tubes flicked to suspend any 
remaining material.  
3 -Tubes were incubated at room temperature for 5 minutes, inverted 6-8 times to mix and flicked 
at the bottom then incubated for an additional 5 minutes at Room temperature. At the end of the 
second incubation period, tubes were inverted 6-8 times and the bottom flicked. 
4- Tubes were centrifuged for 25 seconds at 10,000 x g. 
5- The supernatant (lysed RBCs) was discarded leaving approximately 25 ul with the pellet and 
then vortexed to re suspend the white blood cells.  
6- 300µl of Lysis buffer 2 ( 10%SDS, protease K solution,1mg protease K in 1 % SDS and mM 
Na2EDTA] were added, then the cells were pipetted up and down 5-7 times for complete 
suspension and lysis. Then, 250 ul of the Precipitation Solution (6M NaCl) was added to the 
mixture, mixed vigorously by vortex, followed by centrifugation for 10 minutes at 10,000 x g. 
 
 
26 
 
7- The supernatants was transferred into a clean microfuge tube, 700 ul of ice-cold isopropanol 
was added to precipitate the DNA after gentle mixing 
8- DNA was pelleted after following centrifugation at 4° C for 10 minutes at 10,000 x g. 
9- The supernatants were carefully discarded without dislodging the pellets, washed by absolute 
ethanol, allowed to dry in the air and the DNA is resuspended in 100 µl sterile distilled water.  
10- Purified suspended DNA was stored at -20° C until further use for genomic analysis. 
DNA quality was tested by gel electrophoresis prepared by dissolving 1 gm of agarose in 100 ml 
TAE buffer to obtain 1% agarose. The purity and concentration of DNA sample was evaluated 
through measurements with nanodrop (Nanodrop 2000 C) and all samples had A260/A280 ratio 
above 1.7.Table 2.1 shows some of the obtained data regarding DNA purity and concentration. 
Table 2.1: Concentration and purity of representative DNA samples.  
DNA sample DNA conc. 
ng/μl 
A260 A280 260/280 260/230 
1 228.5 4.569 2.360 1.94 2.09 
2 175.1 3.502 1.867 1.88 1.82 
3 161.1 3.223 1.687 1.91 1.85 
4 235.8 4.717 2.446 1.93 1.93 
5 874.7 17.493 9.342 1.87 1.77 
 
 
 
2.4.2 PCR Amplification  
We performed conventional polymerase chain reaction (PCR) to amplify the targeted area of the 
gene contained the indicated SNP. We used a ready-mix PCR tubes (Syntezza) that contain 
lyophilized mixture of Taq polymerase, Mgcl2, dNTP and buffer. the PCR reaction was run in 25-
µl reaction volume containing 150 ng reverse primer, 150 ng forward primer, 22 µl distilled water 
and 1 µl DNA template. 
 
 
27 
 
 
The sequence of the primer and the PCR program used in the amplification was according to 
(Nascimento et al., 2016). Table 2.2 illustrate the primer sequences and the size of each 
amplification product containing every sequence of the variant in the gene 
 
Table 2.2: Sequence of the primers needed to amplify the DNA fragment containing the two indicated SNP 
SNP 
 
Primer sequence (5’-3’)  
 
Product (bp)  
 
rs 2710102  
 
ATGGATGGACTGACCGATTG 
TTGTGTTGTTTGGCCATGAT  
 
198  
 
rs 7794745  
 
CAACATTGATCCCTTCAGCCAT 
CTCACCAGTGTGCTTCAGACCA  
 
311  
 
 
The PCR program for each variant was as following:  
1- Initial denaturation at 95° (5 min)  
2- 35 cycles of denaturation at 95°C for1 min, annealing at 59°C for 30 second, and extension at 
72°C for 30 second    
3- Final extension at 72°C for 5 min. 
After running the PCR program, the amplified DNA fragment were visualized using 10 µl PCR 
mix and utilizing 2% agarose gel and 7-µl 50 bp DNA ladder. 
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 2.4.3 Restriction Fragment Length Polymorphism (RFLP) 
RFLP analysis of the PCR product was performed utilizing restriction enzymes described by 
Nascimento et al., 2016 as outlined in table 2.3 
Table 2.3: the indicated restriction enzymes for every studied variant and the cut position.  
 
 
The enzyme digestion protocol for each PCR amplified fragment was performed in 15 µl reaction 
volume using the following reaction: 
10 µl PCR mix  
1.5 µl 10 x enzyme buffer  
0.2 ml (54 units of enzyme) 
3.3 µl distilled water.  
The mix was incubated at 37 °C for 1 hour followed by running the mix in 3% agarose by 
dissolving 3 gm agarose gel in 100 ml of TAE buffer, and using 50 bp DNA marker ladder to 
analyze the obtained fragment  
 
 
 
SNP  
Restriction 
enzyme  
 
Allele (bp)  
 
rs 2710102  
 
AvaI (Eco881)  
 
C (43/155)  
 
T (198)  
 
rs 7794745  
 
Tsp509I  
 
T (78/223)  
 
A (311)  
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2.4.4 Sequencing Analysis  
 Several random samples (four samples) were subjected to direct DNA sequencing to validate the 
genotyping result. After PCR Purified DNA fragments were sequenced, using API 3500 automated 
sequencer in the molecular genetic center at the Arab American University .and the DNA sequence 
was compared to the corresponding sequence of the CNTNAP2 gene using BLAST analysis in the 
NCBI  
2.4.5 Statistical Analysis 
The significance of the association between the indicated haplotypes and the disease and its various 
clinical impacts regarding other related information were analyzed using SPSS version 20. The 
Hardy- Weinberg equilibrium was calculated through the http://.oege.org/software/hwe-mr-calc.shtml 
website.  
2.4.6 Ethical Consideration 
All participating subject’s parents were i.nterviewed to fully explain for them or their parents the 
purpose of the intended project, its significance and potential impact. At the end of the interview, 
the parent’s subjects were required to sign a consent form declaring their acceptance to participate 
in the study. All private information regarding patient’s identity and medical information was 
firmly kept confidential and all participants retain the full right to withdraw their participation in 
the study at any time during the process. 
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Chapter Three  
 
Results 
3.1 patient’s record 
Forty-five patients were recruited from several societies located in different cities in the west bank 
including Ramallah, Nablus, and Jenin. However, five of the recruited patients did not have their 
detailed clinical data available. Table 3.1 shows detailed description of the forty patients with their 
clinical data included in the study. The age of the patient is ranged from 4 -16 years of age. Five 
of the recruited patient’s did not have their detailed clinical data available. During the collection 
of patient’s samples, the number of autism patients provided by the various societies was much 
higher than expected based on authentic clinical diagnosis of autism by the specialized physicians 
who followed these patients in those societies. Many of the indicated patients suffered from other 
neurological disorders. In addition, several of the patients guardians refused to include the affected 
children. We found only one patient with sibling affected with the disease. Concerning 
consanguinity, 25% of the patients (10/40) parents are directly related. In addition, 60.3% (25/40) 
of the patients showed normal self-behavior while 15 % (6/40) have aggressive behavior and 20% 
(9/40) showed moderate aggressive behavior. In relation to their language skills 50% (20/40) of 
the patients have significant difficulty in theirs ability to express their needs directly using their 
language ability, while 50% (20/40) were able to communicate clearly by verbal language to 
express their needs. Moreover, about 35% (14/40) of the patients showed normal self-expression 
in response to their environment, about 10% of the patients (4/40) showed moderate self-
expression, and about 15% (6/40) showed minor expression and about 44% (16/40) failed to 
express self-expression. The patients’ behavioral data was determined by social worker employee 
in the indicated societies and extracted from their medical records. This disease related 
complications were later correlated with the various haplotypes obtained from the two indicated 
SNP locations rs 2710102 and rs 7794745 in the gene. 
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Table 3.1: Patients medical records involved in the study 
 
Patient number Society Code Age Sibling Consiguinty Self Behavior  language Skils Self Expression rs 2710102 rs 7794745
1 Farah M.A 6.9 N N Normal Y Normal CT AT
2 Farah M.D 8 N N Aggressive Y Moderate TT AA
3 Farah KH.H 9.4 N Y Normal N Normal CT AT
4 Farah A.K 7.2 N N Normal N Moderate TT AT
5 Farah M.H 8.9 N N Normal N Normal CT AT
6 Farah A.KH 8.8 N Y Normal N Moderate CC AT
7 Farah A.S 5.4 N N Normal N Normal CC AA
8 Farah S.A 7.3 N N Normal Y Normal CT AT
9 Farah Y.S 4.8 N Y Normal Y Normal CT AT
10 Yasmine M 9 N Y Aggressive N None CT AT
11 Yasmine R 5 N N Normal N Minor CC AA
12 Yasmine M.GH6 N N Normal Y Moderate CT AA
13 Yasmine S 9 N N Normal Y Normal TT AT
14 Yasmine A 5 N N Aggressive N None CC AA
15 Yasmine AS 7 N N Normal Y Normal CT AT
16 Yasmine H 11 N N Moderate Y Normal CC AT
17 Jod  A.A 6 N N Normal Y Minor CT AA
18 Jod A.M 7 N N Moderate Y Minor TT AT
19 Jod M 4 N Y Aggressive Y Minor CT AT
20 Jod M2 8 N Y Moderate Y None CT AT
21 Jod Y 4 N Y Moderate N Minor TT AT
22 Ghad S.R 12 N N Normal Y None TT AA
23 Ghad M.R 8 N Y Normal N None TT AT
24 Ghad A.Z 12 N Y Normal y None TT AT
25 Ghad M 11 N N Normal N None CT AT
26 Ghad M.A1 14 N N Moderate N Normal CC AT
27 Ghad A.B 9 N N Normal N None TT TT
28 Ghad W 9 N N Normal N None CT AT
29 Ghad A.B 10 N N Normal Y Minor CC AT
30 Ghad Y 8 N N Normal Y Normal CC AT
31 Ghad Y.Z 16 Y N Moderate Y Normal CT AT
32 Ghad A11 N/A N/A N/A N/A N/A N/A TT TT
33 Ghad M.M 10 N N Moderate N None CT AT
34 Rawan B.S 6 N N Moderate Y Normal CC AA
35 Rawan B 9 N N Normal N None TT AA
36 Rawan N.A 5 N N Normal N None TT AA
37 Rawan A7 N/A N/A N/A N/A N/A N/A TT AA
38 Rawan A8 N/A N/A N/A N/A N/A N/A TT AA
39 Amal H.D 12 N N Normal N None TT AT
40 Amal A3 12 N N Normal N None TT AA
41 Amal M3 9 N Y Moderate N Normal CC TT
42 Amal A5 9 N N Aggressive Y None TT AA
43 Amal A6 8 N N Aggressive Y None TT AT
44 Amal A9 N/A N/A N/A N/A N/A N/A CT AT
45 Amal A10 N/A N/A N/A N/A N/A N/A CC AT
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In this study 145 control subjects, where used including adult university students who are not 
affected from neurological disorder and nor any of their siblings.  
 
3.2 DNA quality 
Figure 3.1 shows representative gel for the purified genomic DNA from 12 participants in the 
study, the gel shows intact high molecular weight DNA bands without any sign of damage and Or 
additional bands in the gel.  
 
Figure 3.1: Quality of genomic DNA prepared from patients and control. Lane 1-12: DNA samples, Lane 13: 
negative control. Lane 14: 100 bp DNA ladder  
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3.3 PCR amplified gene fragments. 
 
 After performing PCR amplification of the DNA fragments containing the indicated haplotypes, 
fraction of the PCR mix was tested to validate the size of the amplified product and compare it to 
the reference size for each DNA fragments containing the indicated SNPs. Figure 3.2. Shows 
representative gel for eight samples of each amplified DNA fragment .The result here showed a 
single 311bp DNA fragment with the rs 2710102 SNPs and a 198 bp fragment with rs 7794745 
haplotypes. The size of both DNA product are in exact agreement with expected fragment size.  
 
 
Figure 3.2: Gel electrophoreses showing PCR amplified DNA fragments containing the rs7794745 and rs 2710102 
SNPs. Lanes1-8 on the right side of the figure shows 198 bp fragment for the rs 2710102 SNPs and lanes 9-16 on the 
left side of the figure shows 311 bp amplified fragments the rs7794745. Lane 17 shows 50 bp DNA ladder. 
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3.4 PCR-RFLP analysis 
Figure 3.3 shows representative RFLP analysis of the two indicated SNPs variants rs 2710102 and 
rs 7794745. The upper part of the Figure shows digestion pattern of 19 control samples (lanes 1-
19) with ava1 restriction enzyme for the rs 2710102 haplotypes and the lower part of the gel shows 
the digestion pattern of 19 control samples digested with Tsp restriction enzyme for the  rs7794745 
haplotypes as indicated on the figure. Lane 12 shows CC genotype, lanes 
1,3,4,5,7,8,9,11,14,15,18,19 shows CT haplotypes and the remaining samples shows TT 
haplotypes. The lower panel of the figure showing the haplotypes rs 7794745. Lane 2 haplotype is 
TT, Lanes 5,13,14,16 haplotypes are AA and the rest of samples are AT. 
 
 
 Figure 3.3. Gel electrophoresis showing PCR-RFLP analysis for selected control samples. The upper part of the 
figure shows the results of aval digestion (Lanes 1-19). The lower part of the gel shows the result of the Tsp 
digestion (1-19). Lane 20: 50 bp DNA ladder 
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Regarding samples in the upper panel in figure 3.4, Lanes 1, 3,5,8,9 shows haplotype CT. Lanes 
2, 4: haplotype TT. Lane 6, 7 haplotype CC. regarding samples in the lower panel. Lanes 1,3,4,5, 
6, 8, showing AT haplotypes .lanes 2, 7 shows AA haplotype and lane 9 shows TT. 
 
 
Figure 3.4 Gel electrophoresis showing PCR-RFLP analysis for selected patient’s samples. The upper part of the 
figure shows the results of aval digestion (Lanes 1-9). The lower part of the gel shows the result of the Tsp digestion 
(1-9). Lane 10: 50 bp DNA ladder 
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3.5 Direct DNA Sequencing results. 
Four selected amplified DNA fragments were subjected to direct DNA sequencing analysis to 
confirm the genotype of these amplified fragments. Four representative sequences showing two rs 
2710102 genotype (homozygous CC and heterozygous CT) in panel A of figure 3.5 and two rs 
7794745 genotype (homozygous AA and heterozygous AT) in panel B of figure 3.5 as indicated 
by the arrows .These genotypes exactly matches the relevant genotypes of the same samples 
obtained by RFLP analysis. 
 
A                                              
              
 
 
 
 
 
 
 
 
 
37 
 
 
B 
            
 
Figure 3.5: Panel A: representative sequencing result of selected DNA samples regarding the rs 2710102 variant. The 
Left side sequence shows CC homozygous genotype and right side sequence shows CT heterozygous genotype. The 
lower part of the panel shows exact sequencing alignment. Panel B: representative-sequencing data regarding rs 
7794745 variant. Left panel shows AA genotype homozygous and right panel shows AT heterozygous genotype. The 
Lower part of the panel shows exact sequencing alignment   
 
3.6 Statistical correlation of the indicated genotypes for rs 2710102 and rs 
7794745 sites with the disease. 
The genotype distribution in the two variants was tested for Hardy- Weinberg equilibrium and 
the p value was 0.51 for the control group and 0.56 for the case group regarding the rs 2710102 
variant. Regarding the rs 779454 variant the p value was 0.54 for control group and 0.63 for the 
case group.  
Among the three various genotypes of the rs 2710102 (CC, TT, CT) the CT genotypes showed 
significant correlation between patients and control subjects (p value 0.043) as shown in table 3.2  
This result Indicates the CT genotypes is associated with healthy subjects, while the other two 
genotypes (CC, TT) showed no significant difference between the control and patients groups. 
 However, none of the three genotypes of the rs 779454 haplotype (AA, TT, AT) showed any 
significant difference between the two groups. These results indicate the two sites do not seem to 
represent susceptible predicting genetic marker for autism.  
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The observed comparison of indicated genotypes in the two sites are not expected to be different 
if more patient’s subjects were included due to the fairly high number of control subject (145) in 
comparison to the patient’s subjects (45).  
 
Table 3.2: Correlation of the indicated genotype between control and case with the disease status. 
 
 
Next, the correlation between the individual genotypes of both SNPs sites between patients and 
control subjects was evaluated. As shown in table 3.3, none of the individual genotypes of both 
sites showed any significant difference between control and patients subjects. This is clearly 
indicated with subjects having the C genotype (CC) in comparisons with subjects having the T 
genotype (CT+TT) of the rs 271012. Similarly the same results were obtained after comparing 
subjects with the A genotype (AA) with those having the T genotype (AT+CT) of the rs 7794745. 
This result here more strongly support the notion that the various genotypes of the two indicated 
SNPs sites do not represent predicting genetic marker for autism as indicated above in table 3.1 
Table 3.3: correlation of combined individual genotypes of the indicated haplotypes with the disease status. 
GROUP  GENOTYPING FREQUENCY  
(rs 2710102) 
 P VALUE   ODDRATIO  
 CC CT+TT     0.523              1.294 
CONTROL  29 116  
AUTISM 11 34  
Genotype 
(rs 7794745) 
Healthy control 
(N=145) 
ASD (N=45) P value   Odd ratio (95%CI) 
AA 38 (26%) 15 (33.3%) 0.352 0.710 (0.3-1.4) 
TT 25 (17%) 3 (6.7%) 0.08 2.917   (0.83-10) 
AT 82 (57%) 27 (60%) 0.683 0.868 (0.4-1.7) 
Genotype 
(rs 2710102)  
Healthy control 
(N=145) 
ASD  
(N=45) 
P value  Odd ratio (95%CI) 
CC 29 (20%) 11 (24%) 0.532 0.773(0.3-1.7) 
TT 33 (23%) 16 (36%) 0.086 0.532 (0.259-1.1) 
CT 83 (57%) 18 (40%) 0.043 2.008 (1-3.9)  
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GROUP  GENOTYPING FREQUENCY  
(rs 7794745) 
 P VALUE   ODDRATIO  
 AA AT+TT  
CONTROL  38 107  0.353                  1.408 
AUTISM 15 30  
 
Since Most of the affected subjects with autism are males while females represent only small 
fraction (4/45 , 9%) while the control subjects comprised of both males and females (44%) males 
64/145 and (56%) females 81/145, the distribution of various genotypes between females and 
males in control subjects was evaluated. As shown in table 3.3, all genotypes of both rs 2710102 
and rs 7794745 showed no significant differences between males and females subjects. Therefore, 
all control subjects were included in our correlation evaluation. However, the correlation between 
the various genotypes and gender between control and autism patients is of no significant since 
the number of female’s patients is very limited. 
Table 3.4: distribution of various genotypes rs 2710102 and rs 7794745 between males and females subjects. 
  rs 2710102      
Gender CC P value  CT  P value TT P value 
F (N=81) 15 (18.5%) 0.616 49 (60.5%) 0.373 17 (21%) 0.567 
M (N=64) 14 (22%)  34 (53%)  16 (25%)  
 
 
GROUP  GENOTYPING FREQUENCY 
(rs 2710102)   
 P VALUE   ODDRATIO  
 TT CT+CC 0.086                  0.534 
CONTROL  33 112  
AUTISM 16 29  
GROUP  GENOTYPING FREQUENCY  
(rs 7794745) 
 P VALUE   ODDRATIO  
 TT AT+AA  
CONTROL  25 120  0.08                      2.917 
AUTISM 3 42  
  rs 7794745     
Gender AA P value AT P value TT P value 
F (N=81) 23 (28.4%) 0.5 46 (56.8%) 0.948 12(14.8%) 0.384 
M (N=64) 15 (23.4%)  36 (56.3%)  13 (20.3%)  
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The interaction between the various genotypes of both sites were correlated between control and 
autism subjects as shown in table 3.5. Interestingly two combinations showed significant 
difference between the two groups. The TT genotype of the rs 271012 in combination with the TT 
genotype of the rs 7794745 showed significant difference, between the two groups. Furthermore, 
the CT genotype of the rs 270102 in combination with AA genotypes of the rs 7794745 showed 
very significant difference in comparison with the TT genotypes of the rs 270102 in combination 
with AA genotype of the rs 7794745 between the two groups (p value 0.003). These results here 
strongly suggest the three indicated genotypes combinations could represent strong predictors for 
autism. This could have important application in providing an early genetic marker for individuals 
affected by the disease, which could provide a tool for very early intervention and care for these 
patients. 
Table 3.5: correlation between haplotypes combination rs 2710102 and rs 7794745 in control and autism patients. 
 
 
 
 
 
 
 
 
 
*Genotype from rs 2710102 vs genotype from rs 7794745 polymorphisms 
 
3.7 Correlation between the genotypes of the rs 2710102 and rs 7794745 
haplotypes with various clinical expression of the diseases.  
In order to evaluate the link between the various genotypes of the rs 2710102, rs7794745 sites, 
and the clinical expression of the disease. The correlation between the various individual 
genotypes and genotype combinations in the two indicated sites with the main observed clinical 
and behavioral complications expression of the disease including self-expression, aggressivity in 
behavior and use of language and consanguinity among patient’s parent was investigated. Table 
Genotype combination*  P value 
CC VS AA 0.701 
CC VS TT 0.092 
TT VS AA 0.550 
TT VS TT 0.04 
CT VS AA 0.132 
CT VS TT 0.367 
CT VS AT 0.220 
CC VS AT 0.735 
TT VS AT  0.303 
CT+AA VS TT+AA 0.003 
CT+AT VS CC+AA 0.335 
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3.6 shows interestingly the presence of significant correlation between higher self-expression with 
the C (CC+CT) allele of the rs 2710102 site in comparisons with the homozygous TT genotype (p 
value 0.0170). No significant correlation could be detected between the all other individual various 
genotypes of either sites (rs 270102 and rs 7794745) and their allele combinations with the three 
indicated disease complications. It is not clear at this point the exact meaning or use of the single 
detected correlation with self-expression in these patients at this level. However, it may indicated 
a potential specific link between this genotype with the self-expression complication of the disease 
that could provide potential marker for early specific therapeutic intervention with these patients 
in relation with this complication. 
Table 3.6: correlation between haplotypes and patients major altered behavior 
 
 
 
 
 
 
 
 
 
Record rs 2710102 rs 7794745 
Self-expression  CC+CT > TT, (p 0.017)  Non-significant 
Aggressivity in behavior  Non-significant  Non-significant 
Language  Non-significant  Non-significant  
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Chapter Four  
 
Discussion  
 
The impact role of the CNTNAP2 gene, a member of the expanded Neurexin gene superfamily,    
on the development of autism (ASD) and many related disorder such as dyslexia, language 
impairment, epilepsy and schizophrenia is clearly evident (Rodenas-Cuadrado, Ho & Vernes, 
2013). Genomic variants in CNTNAP2 gene has been positively and negatively linked to autism 
with varying results in different populations. (Scott-Van Zeeland et al., 2010, Nascimento et al., 
2016, Arking et al., 2008, Zare, Mashayekhi & Bidabadi, 2017, Li et al., 2010, Peñagarikano et 
al., 2011). Since no genetic marker has been linked to ASD development among Palestinian 
patients, the present study was initiated to investigate the potential association between specific 
selected CNTNAP2 gene variants as an early genetic marker that might be involved in the 
prediction of the risk of autism development and consequently provide a lead to initiate early 
medical intervention and subsequently better disease management. The present study represents a 
pioneer investigation towards understanding the molecular genetics of autism and the association 
of polymorphisms in the CNTNAP2 gene with autism among these patients as a major step leading 
towards more extensive understanding of molecular mechanism of CNTNAP2 gene role in the 
disease. Evidently, the association of two variants in the CNTNAP2 gene on the risk of developing 
autism provides insight regarding the linkage of the gene variants with the ASD development in 
the Palestinian patients and provides the bases for subsequent extensive functional studies of the 
exact gene role in the process.  
A significant difference was evident between the frequency of the heterozygous CT genotype in 
the rs2710102 variant between patients and control subjects indicating this genotype is 
significantly associated with healthy individuals and seems protective against ASD. Even though 
the CT genotype of the rs270102 showed a significant difference between the two groups, however 
it represents a weak marker for predicting the disease development. None of the previous studies 
reported a link between this genotype and autism. (Scott-Van Zeeland et al., 2010, Nascimento et 
al., 2016, Arking et al., 2008, Zare, Mashayekhi & Bidabadi, 2017, Li et al., 2010, Peñagarikano 
et al., 2011).  
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No significant difference between either the homozygous CC or homozygous TT of the rs2710102 
variant site could be detected between ASD patients with healthy control subjects which is in 
agreement with many studies in  different populations (Whalley et al., 2011; Nascimento et al., 
2016; Sampath et al., 2013; Jonsson et al., 2014). However, previous studies found significant 
association between this variant in the CNTNAP2 gene and autism complications including 
impaired language skills and social anxiety (Peñagarikano & Geschwind, 2012). Interestingly, in 
a study done in the US population on selective mutism, a disorder related to autism with deficits 
in social communication and interaction, a significant association was reported between this 
variant in rs2710102 of the CNTNAP2 gene and this disease (Stein et al., 2011) 
Regarding the rs7794745 variant in the CNTNAP2 gene, no significant difference in the frequency 
of all tested genotypes (homozygous or heterozygous) and ASD was detected, similar to previous 
studies in different populations including Swedish populations (Jonsson et al., 2014), Korean (Yoo 
et al., 2017) and Spanish (Toma et al., 2013) populations. However, a study in the Brazilian 
population found a significant association between the TT genotype in this variant and autism 
(Nascimento et al., 2016). Regarding the rs7794745 variants, the AT genotype was found to be 
significantly associated with ASD in Iranian (Zare, Mashayekhi and Bidabadi, 2017) and AT in 
Chinese ASD patients (Li et al., 2010) also similar findings were reported in the US population 
(Arking et al., 2008). It should be mentioned here that the Palestinian population have diverse 
genetic background of a Caucasian origin different from the European, Chinese or US populations, 
which might have an impact on the overall results obtained in the present study and their link ASD 
development. 
Interestingly, specific interaction between SNPs variants in the two indicated sites (rs2710102 and 
rs7797745) showed significant difference between the two subject groups. Specifically, the 
combination of TT genotype of the rs2710102 variant and the TT genotype of the rs7794745 
variant (TT+TT) showed a significant higher association with the control subjects compared to the 
ASD group indicating its protective role against the disease. In addition, the combination of the 
CT genotype of the rs2710102 variant and the AA genotype of the rs 7794745 variant (CT+AA) 
versus the combination of TT genotype of the rs 2710102 variant and the AA genotype of the rs 
7794745 variant (TT+AA) showed the CT+AA genotype combination is strongly associated with 
the control group while the TT+AA genotype combination was is strongly associated with ASD . 
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No previous studies showed similar correlation between the combined genotypes of the two 
indicated variant sites and the risk of ASD development. This could represent a strong genotype 
marker of the CNTNAP2 gene role in the development of ASD. 
In relation to the association between the various genotype of the two indicated haplotype sites 
with various clinical symptoms of autism, one significant difference was evident with the ability 
for self-expression where the C allele (CC+CT) was significantly higher than the T allele (TT) in 
the rs2710102 variant among the ASD group compared and therefore represents a risk genotype 
for this symptom. No significant association could be detected between the other reported clinical 
symptoms and all other genotypes in the two indicated sites. Only one previous study showed the 
rs2710102 variant had significant impact on language skills while rs7794745 variant had no 
significant impact on the same symptom (Whitehouse et al., 2012).   
The functional impact of the various genotypes in the indicated variant sites, rs2710102 and 
rs7794745 and the development of ASD and its clinical symptoms is not clear at this stage. Both 
variants are located in intronic sequences (intron 2 for rs2710102 and intron13 for rs7794745) that 
could be involved in gene expression regulation of the CNTNAP2 gene through participation of 
potential transcription factors binding to the DNA sequence around these sites.  A previous report 
regarding the expression of the CNTNAP2 gene and ASD showed a strong association between 
the reduced expression level of the gene during neuronal development evidently represents a risk 
for ASD development (Chiocchetti, A. et al 2014). In that study, four novel mutant variants were 
identified that altered the specific transcription factors binding sites in the promoter region which 
caused decreased level of the promoter activity and association with the risk of ASD. These 
activities were confirmed by reporter systems activities in various cell lines. These promoter 
variants seem to be involved in the upregulation of the gene during neuronal differentiation and 
therefore protect against ASD while mutant variants in these sites resulted in decreased expression 
of the gene associated of high liability of ASD (Chiocchetti, A. et al 2014). One of the indicated 
variants in the promoter (rs71781329) showed association with language development and delayed 
onset of speech.  The reported mutant variants in the indicated sites were proposed to either 
decrease the affinity of the specific transcriptional factors to these sites or results in damaging 
mutations in their recognition sites both of which lead to decreased expression level of the gene. 
The exact functional role of the described variants in the two investigated sites needs further 
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exploration and investigation. It is evident that a DNA binding site for the FOXP2 transcription 
factor is located in intron 1 of the CNTNAP2 gene, which is linked to language development 
(Vernes SC. et al 2008). Therefore the present identified variants in the studied variant sites is very 
likely to affect the activity of specific transcription factors in these locations that are involved in 
the differential expression level of the gene resulting in its impact on the liability of ASD as evident 
with the related promoter variants. This potential effect and those of other related variants in the 
gene will definitely need more extensive investigations to understand the full impact of this gene 
variants on the liability on ASD.    
    
4.1 Conclusion  
The present data in combination with other previous data indicate the contribution of the 
CNTNAP2 gene polymorphisms and mutations on autism seems complex, and require further 
studies to determine its full spectrum of its contribution to the risk of autism development and the 
associated clinical complications as suggested before (Alarcón et al., 2008). No significant 
association was evident between the individual selected CNTNAP2 gene variants (rs2710102 and 
rs7794745) and autism in the Palestinian ASD patients. However, three significant associations 
were evident between specific genotype interactions of the two sites and autism. Based on this 
data, these genotype interactions could represent a marker for development of autism among the 
new born. However, the functional impact of these genotypes at the cellular level needs further 
investigation at the level of gene expression and various potential transcription factors contribution 
in the process. Definitely, the development of autism most likely involves other genes in the 
genome that may provide stronger or weaker impact of the CNTNAP2 gene contribution to the 
development of ASD that require further studies with larger number of patients since this could 
have significant a impact on the various allele distribution (Murdoch & State, 2013). 
 
4.2 Recommendations.  
 
1. Investigate the functional impact of the identified variants on ASD liability and other gene 
variants that are linked to neuronal cognitive or depression disorders.    
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2. Expand the study to include a more patients and their families regarding the various 
CNTNAP2 gene variants.  
3. Analysis of the association of other SNPs of CNTNAP2 gene with ASD.  
4. Subject various patients genome for whole exome sequencing analysis. 
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مرضى التوحد  مع 2PANTNCجين ال  في( )2010172sr 5474977srالعلاقة بين المتغيرين الجينين 
 الفلسطينيين
 
 
  القيقاعداد: مهند سعيد سليمان 
 اشراف: د. هشام درويش
 
 الملخض:
 أو الاجتماعي والسلوك التواصل عدم مثل متفاوتة شدة مع مختلفة عيوب على ينطوي الذي العصبي النمو اضطراب هو التوحد
 كبيراً  دوراً  تلعب بالتوحد قدللإصابة الوراثية  الخلفية أن يعتقد ذلك ومع مجهولا،ً التوحد سبب زال ما الآن، حتى. الكلام تطوير
  الاضطراب هذا في
التي تناولت شعوب  ةالدراسات السابق من بالتوحد في العديد لإصابةمع ا 2PANTNCالمتغيرات الجنية في جين  ارتبطت 
في جين  )2010172sr( و )5474977sr(المتغيرات الجنية  ارتباط مدى عن للتحري مهتمين كنا وبالتالي أخرى.
 مع مرض التوحد في المرضى الفلسطينيين. 2PANTNC
تم استخدام  .الأصحاء الأفراد من 541و التوحد مرضى من 54 شملت الدراسة.8102و 6102 عامي بين دراسةال يتأجر
وقد تم جمع البيانات الطبية للمرض من الجمعيات  المرض والاصحاء لدىالمتغيرات الجينية  لتحديد( PLFR-RCP )تقنية
  .والمراكز المختصة
 أيضا لمقارنة البيانات الطبية للمرضىو صحية مجموعةالو التوحد في المتغيرات الجينية في مجموعة الوراثي التوزيع لمقارنة
 SSPSتم استخدام برنامج ال 
الفلسطينيين لكن عن طريق  مرضىال داخل والتوحد 5474977و 2010172 المتغيرات في مهم ارتباط أي على عثري لم
 التفاعل ما بين المغيرات فد نكون توصلنا الى ارتباط قوي مع مرض التوحد 
 
